Beyond Air, Inc. has built a reputation on its LungFit PH System addressing respiratory conditions, representing its established commercial core. Recently, it initiated a strategic shift by agreeing to majority acquisition of NeuroNOS Ltd., its autism-focused biopharmaceutical arm, by XTL Biopharmaceuticals. This transaction underscores a calculated repositioning that could unlock value yet is fraught with completion uncertainties that expose financial and operational risks. The company holds strong liquidity despite ongoing net losses, but sustaining innovation and navigating regulatory challenges will test its competitive moat going forward.